Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCMSCs in Refractory ARDS
NCT03608592Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2018
- Primary completion
- Aug 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of human umbilical cord mesenchymal stem cells in acute respiratory distress syndrome (ARDS), sponsored by Sun Yat-sen University. Primary endpoints: Infusion associated events at 24 hours and Mortality at 60 days. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT03608592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03608592.